Skip to main content

Nausea and Vomiting, Postoperative

6
Pipeline Programs
6
Companies
5
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
2
2
2
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

Acacia Pharma
BARHEMSYSApproved
amisulpride
Acacia Pharma
Dopamine-2 Receptor Antagonist [EPC]intravenous2020

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Acacia Pharma
Acacia PharmaUK - Cambridge
2 programs
1
1
Amisulpride InjectionPhase 2/31 trial
Rescue Post-Operative Nausea and VomitingN/A1 trial
Active Trials
NCT04954365Withdrawn0Est. Dec 2024
NCT05546359Completed453Est. Jun 2025
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
1
dexamethasonePhase 41 trial
Active Trials
NCT04563494Completed127Est. May 2023
ViiV Healthcare
ViiV HealthcareNC - Durham
2 programs
2
GW679769Phase 3
casopitantPhase 3
Amicus Therapeutics
Amicus TherapeuticsPA - Philadelphia
1 program
1
amisulpridePhase 2/3
GSK
GSKLONDON, United Kingdom
2 programs
GW679769PHASE_31 trial
casopitantPHASE_31 trial
Active Trials
NCT00326248Completed482Est. Jul 2006
NCT00334152Completed515Est. Jul 2006

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Colorado Therapeuticsdexamethasone
GSKGW679769
GSKcasopitant
Acacia PharmaAmisulpride Injection
Acacia PharmaRescue Post-Operative Nausea and Vomiting

Clinical Trials (5)

Total enrollment: 1,577 patients across 5 trials

NCT04563494Colorado Therapeuticsdexamethasone

The Effects of IV vs Oral Dexamethasone on Postoperative Nausea, Vomiting, and Pain

Start: Oct 2020Est. completion: May 2023127 patients
Phase 4Completed
NCT00326248GSKGW679769

Casopitant (Oral) And ZOFRAN To Prevent Postoperative Nausea And Vomiting In Women

Start: Mar 2006Est. completion: Jul 2006482 patients
Phase 3Completed
NCT00334152GSKcasopitant

Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women

Start: Mar 2006Est. completion: Jul 2006515 patients
Phase 3Completed
NCT05546359Acacia PharmaAmisulpride Injection

Study of Intravenous Amisulpride for Prophylaxis of Post-operative Nausea and Vomiting (PONV) in Pediatric Patients

Start: Jan 2024Est. completion: Jun 2025453 patients
Phase 2/3Completed
NCT04954365Acacia PharmaRescue Post-Operative Nausea and Vomiting

Post Operative Nausea and Vomiting (PONV) Rescue Outcomes After Amisulpride Treatment

Start: Nov 2022Est. completion: Dec 20240
N/AWithdrawn

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.